Advertisement
UK markets open in 3 hours 23 minutes

  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     

  • HANG SENG

    17,625.08
    +340.54 (+1.97%)
     

  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     

  • GOLD FUTURES

    2,345.20
    +2.70 (+0.12%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,502.47
    +8.48 (+0.02%)
     

  • CMC Crypto 200

    1,391.88
    +9.30 (+0.67%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Global Infectious Diseases Partnering Deal Trends, Players and Financials Report/Directory 2021

Research and Markets
·5-min read

Dublin, Jan. 12, 2022 (GLOBE NEWSWIRE) -- The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

The Global Infectious Diseases Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 2,600 infectious diseases deals.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.

Report scope

Global Infectious Diseases Partnering 2014 to 2021 includes:

  • Trends in Infectious Diseases dealmaking in the biopharma industry since 2014

  • Access to headline, upfront, milestone and royalty data

  • Access to hundreds of Infectious Diseases deal contract documents

  • Comprehensive access to over 2600 Infectious Diseases deal records

  • The leading Infectious Diseases deals by value since 2014

  • Most active Infectious Diseases dealmakers since 2014

The report includes deals for the following indications:

  • Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications

  • Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.

  • Parasitic

  • Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications

  • Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications

ADVERTISEMENT

In Global Infectious Diseases Partnering 2014 to 2021, available deals and contracts are listed by:

  • Headline value

  • Upfront payment value

  • Royalty rate value

  • Stage of development at signing

  • Deal component type

  • Technology type

  • Specific therapy indication

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are the sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking
2.1. Introduction
2.2. Infectious Diseases partnering over the years
2.3. Infectious Diseases partnering by deal type
2.4. Infectious Diseases partnering by industry sector
2.5. Infectious Diseases partnering by stage of development
2.6. Infectious Diseases partnering by technology type
2.7. Infectious Diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for Infectious Diseases partnering
3.1. Introduction
3.2. Disclosed financials terms for Infectious Diseases partnering
3.3. Infectious Diseases partnering headline values
3.4. Infectious Diseases deal upfront payments
3.5. Infectious Diseases deal milestone payments
3.6. Infectious Diseases royalty rates

Chapter 4 - Leading Infectious Diseases deals and dealmakers
4.1. Introduction
4.2. Most active in Infectious Diseases partnering
4.3. List of most active dealmakers in Infectious Diseases
4.4. Top Infectious Diseases deals by value

Chapter 5 - Infectious Diseases contract document directory
5.1. Introduction
5.2. Infectious Diseases partnering deals where contract document available

Chapter 6 - Infectious Diseases dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Infectious Diseases therapeutic target

Appendices
Appendix 1 - Directory of Infectious Diseases deals by company A-Z since 2014
Appendix 2 - Directory of Infectious Diseases deals by deal type since 2014
Appendix 3 - Directory of Infectious Diseases deals by stage of development since 2014
Appendix 4 - Directory of Infectious Diseases deals by technology type since 2014

For more information about this report visit https://www.researchandmarkets.com/r/m22pph


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900